GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

U.K.-based biopharmaceutical company GSK plc (GSK) said on Friday that the European Medicines Agency (EMA) has accepted its ...

GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest. | ITV National News ...

Blood cancer patients in England will be the first in the world to be offered a 'Trojan horse' drug. Thousands of patients ...

A “TROJAN HORSE” therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a ...

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...